| Citation: |
LUO Wenqing, LI Yuanqi, YE Fei, LI Qiangming, ZHANG Guoqing, LI Xiangnan. Construction and Validation of A Nomogram Prognostic Model for Patients with Lung Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(3): 197-204. DOI: 10.3971/j.issn.1000-8578.2022.21.0623
|
To construct a nomogram prognostic model for predicting the survival of patients with lung adenocarcinoma based on the large sample data from the SEER database.
We retrospectively analyzed the clinical data of patients who were diagnosed with lung adenocarcinoma from 2010 to 2015 in the SEER database. A nomogram model was created based on independent parameters influencing the prognosis of patients with lung adenocarcinoma using Lasso Cox regression analysis. The C-index and calibration curve were utilized to assess the ability to distinguish and calibrate the nomogram. NRI and DCA curves were used to evaluate the prediction ability and net benefit of the nomogram.
A total of 15 independent risk factors affecting the prognosis of lung adenocarcinoma were identified and integrated into the nomogram model. The C-index of the prediction model was 0.819 in the training cohort and 0.810 in the validation cohort. The predicted specific survival rate of the 1-, 3- and 5-year calibration curves of the training cohort and the validation cohort were consistent with the actual specific survival rate. In comparison to the 7th edition of the AJCC TNM staging system, the NRI and DCA curves demonstrated a considerable boost to the predictive capacity and net benefits achieved by the nomogram model. The risk stratification model constructed with this nomogram model was able to distinguish the patients with different risks well (P < 0.0001).
A nomogram prognostic model is successfully developed and validated, which provides a simple and reliable tool for the survival prediction of the patients with lung adenocarcinoma. Meanwhile, the risk stratification model constructed by the prediction model can conveniently screen patients with different risks, which is important for the individualized treatment of lung adenocarcinoma patients.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [2] |
Avelino CUR, Cardoso RM, de Aguiar SS, et al. Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel[J]. J Bras Pneumol, 2015, 41(2): 133-142. doi: 10.1590/S1806-37132015000004367
|
| [3] |
Shi J, Hua X, Zhu B, et al. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study[J]. PLoS Med, 2016, 13(12): e1002162. doi: 10.1371/journal.pmed.1002162
|
| [4] |
Lin JJ, Cardarella S, Lydon CA, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs[J]. J Thorac Oncol, 2016, 11(4): 556-565. doi: 10.1016/j.jtho.2015.12.103
|
| [5] |
Qi L, Li Y, Qin Y, et al. An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy[J]. Br J Cancer, 2016, 115(12): 1513-1519. doi: 10.1038/bjc.2016.370
|
| [6] |
Zhang Y, Zheng D, Xie J, et al. Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study[J]. Chest, 2018, 154(3): 501-511. doi: 10.1016/j.chest.2018.04.040
|
| [7] |
Wo Y, Yang H, Zhang Y, et al. Development and External Validation of a Nomogram for Predicting Survival in Patients With Stage IA Non-small Cell Lung Cancer ≤2 cm Undergoing Sublobectomy[J]. Front Oncol, 2019, 9: 1385. doi: 10.3389/fonc.2019.01385
|
| [8] |
Duggan MA, Anderson WF, Altekruse S, et al. The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship[J]. Am J Surg Pathol, 2016, 40(12): e94-e102. doi: 10.1097/PAS.0000000000000749
|
| [9] |
Shin S, Kang D, Cho JH, et al. Prognostic impact of lymph node ratio in patients with pT1-2N1M0 non-small cell lung cancer[J]. J Thorac Dis, 2020, 12(10): 5552-5560. doi: 10.21037/jtd-20-1611
|
| [10] |
Nakamura H, Saji H. Worldwide trend of increasing primary adenocarcinoma of the lung[J]. Surg Today, 2014, 44(6): 1004-1012. doi: 10.1007/s00595-013-0636-z
|
| [11] |
王高祥, 熊燃, 吴汉然, 等. 中性粒细胞/淋巴细胞比值预测根治性切除肺腺癌患者预后分析[J]. 中国肺癌杂志, 2018, 21(8): 588-593. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201808004.htm
Wang GX, Xiong R, Wu HR, et al. Prognostic Value of Neutrophil-to-lymphocyte Ratio in Patients with Lung Adenocarcinoma Treated with Radical Dissection[J]. Zhongguo Fei Ai Za Zhi, 2018, 21(8): 588-593. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201808004.htm
|
| [12] |
Liao F, Guo X, Lu X, et al. A validated survival nomogram for early-onset diffuse gastric cancer[J]. Aging (Albany NY), 2020, 12(13): 13160-13171.
|
| [13] |
Lin JL, Lin JX, Li P, et al. Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study[J]. BMC Cancer, 2019, 19(1): 873. doi: 10.1186/s12885-019-5993-6
|
| [14] |
Campos-Balea B, de Castro Carpeño J, Massutí B, et al. Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database[J]. Thorac Cancer, 2020, 11(11): 3357-3364. doi: 10.1111/1759-7714.13681
|
| [15] |
Yang H, Li X, Shi J, et al. A nomogram to predict prognosis in patients undergoing sublobar resection for stageⅠA non-small-cell lung cancer[J]. Cancer Manag Res, 2018, 10: 6611-6626. doi: 10.2147/CMAR.S182458
|
| [16] |
Zhou HQ, Zhang YX, Qiu ZT, et al. Nomogram to Predict Cause-Specific Mortality in Patients With Surgically Resected Stage Ⅰ Non-Small-Cell Lung Cancer: A Competing Risk Analysis[J]. Clin Lung Cancer, 2018, 19(2): e195-e203. doi: 10.1016/j.cllc.2017.10.016
|
| [17] |
Pitz MW, Musto G, Navaratnam S. Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort[J]. Can Respir J, 2013, 20(1): 30-34. doi: 10.1155/2013/618691
|
| [18] |
Varlotto JM, Voland R, Mckie K, et al. Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease[J]. Cancer Med, 2018, 7(14): 1211-1220.
|
| [19] |
Zuo Z, Zhang G, Song P, et al. Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort[J]. Ann Surg Oncol, 2021, 28(7): 3941-3950. doi: 10.1245/s10434-020-09362-0
|
| [20] |
田希贵, 刘德森, 汪元玉, 等. 腺癌与其他类型非小细胞肺癌术后临床特点的差异及预后因素分析[J]. 中国癌症杂志, 2017, 27(3): 227-232. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201703011.htm
Tian XG, Liu DS, Wang YY, et al. Postoperative differences in clinical characteristics between adenocarcinoma and other types of non-small cell lung cancer and analysis of prognostic factors of adenocarcinoma treated with surgery[J]. Zhongguo Ai Zheng Za Zhi, 2017, 27(3): 227-232. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201703011.htm
|
| [21] |
彭红, 马美丽, 韩宝惠. 1742例Ⅳ期非小细胞肺癌的预后分析[C]. 上海市肺科学会和美国ACCP联合会议论文集, 2011: 142-148.
Peng H, Ma ML, Han BH. Survival analysis of 1742 cases of Ⅳ non-small cell lung cancer[C]. Proceedings of the Joint Conference of the Shanghai Pulmonary Society and ACCP, 2011: 142-148.
|
| [22] |
冯悦. 168例肺腺癌患者预后因素分析[D]. 承德医学院, 2016.
Feng Y. Analysis of prognostic factors in 168 cases of lung adenocarcinoma patients[D]. Chengde Medical College, 2016.
|
| [23] |
Shi M, Zhan C, Shi J, et al. Prediction of Overall Survival of Patients with Completely Resected Non-Small Cell Lung Cancer: Analyses of Preoperative Spirometry, Preoperative Blood Tests, and Other Clinicopathological Data[J]. Cancer Manag Res, 2019, 11: 10487-10497. doi: 10.2147/CMAR.S232219
|
| [24] |
Sun F, Ma K, Yang X, et al. A nomogram to predict prognosis after surgery in early stage non-small cell lung cancer in elderly patients[J]. Int J Surg, 2017, 42: 11-16. doi: 10.1016/j.ijsu.2017.04.024
|
Figures(5) / Tables(3)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: